GCC Neurodegenerative Disease Market

ID: MRFR/LS/50855-HCR

200 Pages

Rahul Gotadki

September 2025

GCC Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal)-Forecast to 2035

GCC Neurodegenerative Disease Market Research Report-Forecast to 2035 Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Infographic

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

GCC Neurodegenerative Disease Market Summary

The GCC Neurodegenerative Disease market is projected to grow significantly from 583.2 USD Million in 2024 to 1463.6 USD Million by 2035.

Key Market Trends & Highlights

GCC Neurodegenerative Disease Key Trends and Highlights

The market is expected to experience a compound annual growth rate of 8.72 percent from 2025 to 2035.
By 2035, the market valuation is anticipated to reach 1463.6 USD Million, indicating robust growth potential.
In 2024, the market is valued at 583.2 USD Million, reflecting the current demand for neurodegenerative disease treatments in the GCC region.
Growing adoption of innovative therapies due to increasing prevalence of neurodegenerative diseases is a major market driver.

GCC Neurodegenerative Disease Market

CAGR

8.72%

Market Size & Forecast

2024 Market Size	583.2 (USD Million)
2035 Market Size	1463.6 (USD Million)
CAGR (2025-2035)	8.72%

Major Players

Merck, Sanofi, Gilead Sciences, AbbVie, Pfizer, Teva Pharmaceutical Industries, AstraZeneca, BristolMyers Squibb, Johnson & Johnson, Novartis, Sandoz, Biogen, Roche, Eli Lilly, Amgen

GCC Neurodegenerative Disease Market Trends

The GCC Neurodegenerative Disease Market is undergoing significant changes driven by an increasing awareness of neurodegenerative disorders and a growing aging population within the region. Key market drivers include the escalating prevalence of conditions such as Alzheimer's and Parkinson's diseases, largely due to lifestyle factors and genetic predispositions prevalent in GCC countries. National health initiatives in nations like Saudi Arabia and the UAE have begun to prioritize neurological health, leading to improved diagnostic and treatment options.

This awareness is further reinforced by government-funded research projects and collaborations aimed at better understanding these diseases.There are various opportunities to be captured in the GCC Neurodegenerative Disease Market, particularly in the development of innovative treatment modalities, including monoclonal antibodies and gene therapy. Pharmaceuticals and biotech companies are likely to explore partnerships with local health authorities and research organizations in order to advance their product pipelines and address unmet medical needs. Furthermore, rising investments in healthcare infrastructure mean that there is potential for the expansion of specialized clinics and facilities focused on neurological care.

Recent trends highlight a shift toward telehealth and digital health solutions, especially as GCC citizens become increasingly tech-savvy. These platforms offer opportunities for remote monitoring and management of neurodegenerative conditions, making care more accessible. Additionally, there is a noticeable increase in the demand for patient support groups and educational programs within GCC countries, which aim to provide resources and improve the quality of life for patients and their families. The convergence of these trends signifies a proactive approach toward addressing neurodegenerative diseases in the GCC region.

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Market Segment Insights

GCC Neurodegenerative Disease Market Segment Insights

Neurodegenerative Disease Market Disease Type Insights

The GCC Neurodegenerative Disease Market demonstrates a multifaceted landscape, particularly when examined through the lens of Disease Type. This market encompasses a variety of conditions, each with its distinct impact and significance. Alzheimer's Disease stands as one of the most prevalent neurodegenerative disorders, characterized by memory loss and cognitive decline, making it a critical area of focus within the GCC. The region's aging population and increasing life expectancy contribute to a higher prevalence of Alzheimer's, propelling the demand for innovative treatment solutions and care strategies.

Parkinson's Disease, another notable condition in this market, affects mobility and daily functioning, and its increasing incidence is influencing healthcare policies across GCC member states. The response to this condition highlights the growing recognition of neurodegenerative diseases as a pivotal public health issue. Multiple Sclerosis adds further complexity to the Disease Type landscape, impacting young adults predominantly and driving a need for early diagnosis and long-term management solutions.

The increasing awareness of these conditions in the GCC region is fostering partnerships between healthcare providers and pharmaceutical companies to enhance patient care and treatment options.Amyotrophic Lateral Sclerosis presents more unique challenges due to its rapid progression and the significant impact it has on patients and families. The GCC is witnessing a rising focus on research and clinical trials for this rare disease, enhancing the overall understanding and treatment modalities available.Huntington's Disease, while less common, plays an important role in the discourse surrounding genetic disorders in neurodegeneration.

The challenges faced by families affected by this condition showcase the necessity for targeted support and resources within healthcare systems in the GCC.The GCC Neurodegenerative Disease Market continues to evolve, driven by a confluence of factors such as demographic changes, increased disease awareness, and technological advancements in treatment methods. The trends within these Disease Types indicate a movement towards more personalized medicine and comprehensive healthcare approaches, ensuring that patients receive not just treatment but also support throughout their journey.

Neurodegenerative Disease Market Diagnosis Method Insights

The Diagnosis Method segment of the GCC Neurodegenerative Disease Market plays a vital role in accurately identifying various neurodegenerative conditions. It comprises several techniques, including Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, and Electrophysiological Tests. Neurological Examination is critical as it assesses cognitive function, motor skills, and coordination, providing healthcare providers with immediate insights into a patient's neurological health.

Imaging Techniques, such as MRI and CT scans, are essential for visualizing brain structures and detecting abnormalities, which contribute significantly to diagnosis accuracy.Cerebrospinal Fluid Analysis is important for diagnosing conditions like Alzheimer's and multiple sclerosis, as it helps identify biomarkers indicative of various diseases. Lastly, Electrophysiological Tests, which measure electrical activity in the brain and muscles, are crucial in diagnosing certain disorders by assessing nerve function.

The continued advancement in these diagnostic methods is driving growth in the GCC region, with increasing awareness and healthcare initiatives supporting the need for accurate diagnosis of neurodegenerative diseases.As the GCC region invests in healthcare technology, the demand for these diagnostic techniques is steadily rising, reinforcing their importance in the overall Neurodegenerative Disease Market.

Neurodegenerative Disease Market Treatment Type Insights

The Treatment Type segment of the GCC Neurodegenerative Disease Market is varied, encompassing Medication, Therapy, Rehabilitation, and Surgical Interventions, each playing a crucial role in patient care. Medication remains a dominant force, offering various pharmacological options that help manage symptoms and slow disease progression, significantly enhancing patient quality of life. Therapy, including occupational and speech therapy, is becoming increasingly important as healthcare providers focus on improving functional abilities and communication skills among patients.Rehabilitation programs specifically tailored for neurodegenerative conditions are seeing rising significance, as they provide structured support, enabling patients to maintain independence for longer periods.

Surgical Interventions, while less commonly accessed, are critical for certain conditions and can lead to marked improvements in patient outcomes. The GCC's growing elderly population drives demand for these treatment modalities, alongside increasing government investments in healthcare infrastructure and Research and Development initiatives that aim to innovate treatments and improve overall service delivery.With patient-centered care becoming the focus, embracing these various treatment types contributes significantly to personalizing management strategies in the region. Overall, the GCC Neurodegenerative Disease Market segmentation via Treatment Type highlights the multifaceted approach necessary for tackling the challenges posed by these debilitating diseases.

Neurodegenerative Disease Market Route of Administration Insights

The Route of Administration segment within the GCC Neurodegenerative Disease Market is vital as it directly affects the delivery and effectiveness of treatments for patients. The segment encompasses various methods, including oral, injectable, intravenous, and transdermal routes. Oral administration is often favored for its ease of use and patient compliance, making it a significant method for long-term therapies. Injectable routes, including both subcutaneous and intramuscular options, are critical for delivering biologics and medications that require rapid onset of action.Intravenous administration is prominent in hospital settings, especially for acute cases, allowing for immediate therapeutic effects and better control over dosing.

Transdermal methods are gaining attention due to their convenience and ability to maintain consistent drug delivery over extended periods. The GCC region has witnessed increasing investments in healthcare infrastructure and Research and Development, driving advancements in drug formulations and delivery systems. As a result, the demand for innovative delivery methods continues to grow, highlighting the importance of the Route of Administration segment in improving patient outcomes and managing neurodegenerative diseases effectively.This growth is further supported by rising incidences of such diseases, pushing the industry towards developing more efficient delivery solutions tailored to patient needs.

Get more detailed insights about GCC Neurodegenerative Disease Market Research Report-Forecast to 2035

Request Free Sample

Key Players and Competitive Insights

The GCC Neurodegenerative Disease Market is experiencing significant growth and transformation due to increasing awareness of neurological disorders and the rising prevalence of conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. As the healthcare landscape in the Gulf Cooperation Council region evolves, various companies are vying for market share by innovating their product offerings, enhancing research and development capabilities, and forming strategic partnerships.

The market is characterized by a competitive environment where pharmaceutical giants are not only focused on expanding their geographic presence but are also investing in advanced therapeutic solutions to meet the unmet needs of patients suffering from neurodegenerative diseases. As the investment in healthcare technology increases along with heightened governmental and regulatory support, the competitive dynamics are poised to shift further, fostering both innovation and collaboration among key players in the sector.Merck is a notable player in the GCC Neurodegenerative Disease Market, recognized for its robust portfolio of pharmaceutical products aimed at treating various neurological disorders.

The company has established a significant presence in this region, leveraging its extensive research capabilities and a strong commitment to improving patient outcomes. Merck's strengths lie in its innovative approach to drug development, particularly in neurology, where it focuses on finding solutions for complex conditions that require specialized therapies. With a solid infrastructure in place, including well-established distribution networks and marketing strategies tailored to the local market, Merck is well-positioned to capitalize on the growing demand for treatments targeting neurodegenerative diseases.

Its commitment to research and patient-centric initiatives further enhances its competitive advantage in this sector.Sanofi stands out in the GCC Neurodegenerative Disease Market through its comprehensive approach to neurological therapies and a diverse portfolio of key products tailored to patient needs. The company has secured a strong foothold in the region, driven by its ongoing commitment to innovation and collaboration with healthcare providers. Sanofi's strengths include its established reputation for quality and safety in drug development, as well as its focus on personalized medicine, which aims to optimize treatment outcomes for individuals with neurodegenerative disorders.

The company has also pursued strategic mergers and acquisitions to bolster its capabilities and expand its therapeutic offerings in the GCC region. By continuously investing in new technologies and fostering partnerships with local stakeholders, Sanofi is positioned to leverage its strengths effectively, enhancing its market influence and addressing the critical healthcare needs associated with neurodegenerative diseases in the Gulf Cooperation Council countries.

Key Companies in the GCC Neurodegenerative Disease Market market include

Industry Developments

The GCC Neurodegenerative Disease Market has seen significant developments recently, particularly with expansion efforts and new product launches by major pharmaceutical companies. Merck and AbbVie have been focusing on enhancing their portfolios with innovative treatments for conditions such as Alzheimer’s and Parkinson’s diseases. The region has experienced a notable growth in market valuation, driven by an increasing prevalence of neurodegenerative diseases and rising healthcare expenditure. Furthermore, in June 2023, Gilead Sciences announced a strategic collaboration with an undisclosed local healthcare provider to improve access to treatment options in the GCC.

In terms of mergers and acquisitions, AstraZeneca's acquisition of a small local biotech firm focused on neurodegenerative research was publicly confirmed in February 2023, reinforcing its commitment to expanding its presence in the GCC market. The Kingdom of Saudi Arabia is increasingly investing in healthcare infrastructure focused on neurodegenerative diseases, reflecting a broader regional trend towards prioritizing health initiatives. The market dynamics are influenced heavily by the ongoing Research and Development by companies such as Pfizer and Roche, emphasizing novel therapeutic approaches. These developments underscore the growing importance of the GCC Neurodegenerative Disease Market in the global landscape.

Market Segmentation

Outlook

Oral
Injectable
Intravenous
Transdermal

Report Scope

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	552.5(USD Million)
MARKET SIZE 2024	583.25(USD Million)
MARKET SIZE 2035	1463.6(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.724% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Merck, Sanofi, Gilead Sciences, AbbVie, Pfizer, Teva Pharmaceutical Industries, AstraZeneca, BristolMyers Squibb, Johnson & Johnson, Novartis, Sandoz, Biogen, Roche, Eli Lilly, Amgen
SEGMENTS COVERED	Disease Type, Diagnosis Method, Treatment Type, Route of Administration
KEY MARKET OPPORTUNITIES	Aging population growth, Rising prevalence rates, Increased healthcare spending, Advanced research and clinical trials, Emerging telemedicine solutions
KEY MARKET DYNAMICS	Aging population increase, Rising prevalence, Advanced treatment options, Research funding growth, Healthcare infrastructure expansion
COUNTRIES COVERED	GCC

FAQs

What is the projected market size of the GCC Neurodegenerative Disease Market for the year 2024?

The GCC Neurodegenerative Disease Market is expected to be valued at 583.25 million USD in the year 2024.

What will be the market value of Alzheimer's Disease in the GCC region by 2035?

By 2035, the market value for Alzheimer's Disease in the GCC is projected to reach 512.0 million USD.

What is the expected CAGR of the GCC Neurodegenerative Disease Market from 2025 to 2035?

The anticipated CAGR for the GCC Neurodegenerative Disease Market from 2025 to 2035 is 8.724%.

Which company is a major player in the GCC Neurodegenerative Disease Market?

Some of the major players in the market include Merck, Sanofi, and Gilead Sciences.

How much is the market for Parkinson's Disease expected to grow by 2035?

The market for Parkinson's Disease is expected to grow to 350.0 million USD by 2035 in the GCC region.

What is the expected market value for Multiple Sclerosis in the year 2024?

The market value for Multiple Sclerosis in the GCC is projected to be 100.0 million USD in 2024.

What will be the market size of Amyotrophic Lateral Sclerosis in 2035?

By 2035, the market size for Amyotrophic Lateral Sclerosis in the GCC is expected to reach 160.0 million USD.

What are the growth drivers for the GCC Neurodegenerative Disease Market?

Key growth drivers include increasing prevalence of neurodegenerative diseases and advancements in treatment options.

How is the market for Huntington's Disease expected to change by 2035?

The market for Huntington's Disease is anticipated to increase to 191.6 million USD in the year 2035.

What challenges are faced by the GCC Neurodegenerative Disease Market?

Challenges include high treatment costs and the complexity of disease management in neurodegenerative conditions.

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027